Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective treatment of hyperphosphatemia with denosumab in patients with loss of function of FGF23 and high bone density: case series.

Journal of pediatric endocrinology & metabolism : JPEM - 17 Dec 2025

Vafadar Mehdi, Zarei Elham, Dadakhani Sonya, Ziaee Vahid

Abstract excerpt

OBJECTIVES: This study evaluated denosumab for treating hyperphosphatemia in patients with loss-of-function FGF23 mutations and high bone density. METHODS: Three patients with hyperphosphatemia due to mutations in the FGF23 pathway (two FGF23, one GALNT3) were treated. Conventional therapies, including phosphate binders, dietary restriction, and teriparatide, failed to reduce phosphate in the two symptomatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Bone Density

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Density Conservation Agents

Share to Fibroblast Growth Factor-23

Share to Fibroblast Growth Factors

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 41243221
DOI: 10.1515/jpem-2025-0272

Genes

FGF23
GALNT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective treatment of hyperphosphatemia with denosumab in patients with loss of function of FGF23 and high bone density: case series.PMID 41243221Read ↗

Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.Semantic proximity Read ↗

Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?Semantic proximity Read ↗

[Epidemiology of FGF23-related hypophosophatemic diseases].Semantic proximity Read ↗

Hypophosphatemic rickets.Semantic proximity Read ↗

Novel genetic mutation associated with hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome treated with denosumab: a case report.Semantic proximity Read ↗

FGF23 in skeletal modeling and remodeling.Semantic proximity Read ↗

Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.Semantic proximity Read ↗

Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.Semantic proximity Read ↗

Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.Semantic proximity Read ↗

FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.Semantic proximity Read ↗

Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.Semantic proximity Read ↗

Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.